Clinical Trial Update: Targeting the Neurobiology of RRB in Autism Using N-acetylcysteine: Open Label [Phase 2, Phase 3]

View source ↗

Summary

Open-label Phase 2/3 trial at Stanford evaluating N-acetylcysteine for restricted repetitive behaviors in Autism Spectrum Disorder. Enrollment is by invitation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autism Spectrum Disorder

Drugs mentioned

• N-acetylcysteine (N-acetylcysteine)

Snippet

Sponsor: Stanford University | Conditions: Autism Spectrum Disorder | Phase 2, Phase 3 | Status: ENROLLING_BY_INVITATION